Seminars in Cancer Biology

Papers
(The H4-Index of Seminars in Cancer Biology is 82. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation473
Multifaceted role of chemokines in solid tumors: From biology to therapy456
Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation349
Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications292
Targeting Hippo signaling pathway by phytochemicals in cancer therapy260
Editorial Board243
Advances in biology and novel treatments of SCLC237
Small secretory proteins of immune cells can modulate gynecological cancers234
The molecular chaperone TRAP1 in cancer: From the basics of biology to pharmacological targeting233
Emerging applications of bacteria as antitumor agents224
Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator202
Deregulated transcription factors in the emerging cancer hallmarks195
Critical DNA damaging pathways in tumorigenesis192
Origins and molecular effects of hypoxia in cancer187
Erratum to “RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer” [Semin. Cancer Biol. 102–103 (2024) 4–16]187
Editorial Board185
Editorial Board185
Special issue: Deregulated transcription factors in the cancer therapeutic challenges: An update on cancer stemness features184
The impact of obesity and lipids on cancer: Insights into mechanisms and potential interventions184
Innovative trial design in precision oncology179
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy164
Gut microbes in gastrointestinal cancers163
The IL-1 family in tumorigenesis and antitumor immunity159
Molecular targets of tyrosine kinase inhibitors in thyroid cancer152
Genome chaos: Creating new genomic information essential for cancer macroevolution149
Association of Chlamydia and Mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis145
Excess body weight and postmenopausal breast cancer: Emerging molecular mechanisms and perspectives145
Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer144
Immune cellular components and signaling pathways in the tumor microenvironment142
Cracking the Resistance Code:The Molecular Reclassification of Cancer and Precision Therapy Strategies139
Extracellular vesicles associated microRNAs: Their biology and clinical significance as biomarkers in gastrointestinal cancers134
Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics?125
Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse123
Enhancing head and neck tumor management with artificial intelligence: Integration and perspectives120
Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy119
Anticancer properties of chimeric HDAC and kinase inhibitors119
Atrial fibrillation in cancer patients: Epidemiology, identification and management117
Reprogramming of glycolysis by chemical carcinogens during tumor development116
Metabolic landscape and rewiring in normal hematopoiesis, leukemia and aging116
Regulation of the aryl hydrocarbon receptor in cancer and cancer stem cells of gynecological malignancies: An update on signaling pathways116
Anticancer natural products targeting immune checkpoint protein network116
Editorial Board114
Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools113
Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems112
Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer112
The role of deiodinases on metabolic alteration in cancer111
Targeting the “undruggable”: RNA-binding proteins in the spotlight in cancer therapy109
New biological and immunological approaches to cancer therapy: Basic and clinical aspects109
Insight into the role of multiple signaling pathways in regulating cancer stem cells of gynecologic cancers107
Modulation of the tumor microenvironment by natural agents: implications for cancer prevention and therapy107
Therapy-induced modulation of extracellular vesicles in hepatocellular carcinoma107
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine104
Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics104
Cellular stress responses and metabolic reprogramming in cancer progression and dormancy102
Vibrational spectroscopy for decoding cancer microbiota interactions: Current evidence and future perspective99
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors99
The intricacies of NRF2 regulation in cancer99
Curcumin and colorectal cancer: An update and current perspective on this natural medicine99
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics98
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer98
How far have we explored fungi to fight cancer?97
Editorial Board96
Editorial Board95
Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment94
The foundational framework of tumors: Gametogenesis, p53, and cancer93
Analytical demands to use whole-genome sequencing in precision oncology92
Transcription networks rewire gene repertoire to coordinate cellular reprograming in prostate cancer91
BubR1 and SIRT2: Insights into aneuploidy, aging, and cancer91
Metabolic reprogramming of tumor microenviroment by engineered bacteria91
Clinical utility of whole-genome sequencing in precision oncology90
Cytotoxic activity of l-lysine alpha-oxidase against leukemia cells89
Drivers of centrosome abnormalities: Senescence progression and tumor immune escape88
Mechanisms and applications of apolipoproteins and apolipoprotein mimetic peptides: Common pathways in cardiovascular disease and cancer87
Role of ubiquitination-driven metabolisms in oncogenesis and cancer therapy87
Advancements in small cell lung cancer85
The microbiome-immune cell interaction network: Advancing tumor immunotherapy85
The role of RNA processing and regulation in metastatic dormancy85
Functionalized-DNA nanostructures as potential targeted drug delivery systems for cancer therapy84
Chaperonins in cancer: Expression, function, and migration in extracellular vesicles83
The role of tumor microenvironment and exosomes in dormancy and relapse82
Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer82
Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders82
Microbiota and lung cancer82
0.32808899879456